B-intervention	0	9	Tamoxifen
I-intervention	9	10	,
I-intervention	11	20	radiation
I-intervention	21	28	therapy
I-intervention	28	29	,
I-intervention	30	32	or
I-intervention	33	37	both
O	38	41	for
O	42	52	prevention
O	53	55	of
B-condition	56	67	ipsilateral
I-condition	68	74	breast
I-condition	75	80	tumor
I-condition	81	91	recurrence
O	92	97	after
O	98	108	lumpectomy
O	109	111	in
B-eligibility	112	117	women
I-eligibility	118	122	with
I-eligibility	123	131	invasive
I-eligibility	132	138	breast
I-eligibility	139	146	cancers
I-eligibility	147	149	of
I-eligibility	150	153	one
I-eligibility	154	164	centimeter
I-eligibility	165	167	or
I-eligibility	168	172	less
O	172	173	.

O	174	178	This
O	179	184	trial
O	185	188	was
O	189	197	prompted
O	198	200	by
O	201	212	uncertainty
O	213	218	about
O	219	222	the
O	223	227	need
O	228	231	for
O	232	238	breast
O	239	250	irradiation
O	251	256	after
O	257	267	lumpectomy
O	268	270	in
O	271	275	node
O	275	276	-
O	276	284	negative
O	285	290	women
O	291	295	with
O	296	304	invasive
O	305	311	breast
O	312	319	cancers
O	320	322	of
O	323	324	<
O	324	325	/
O	325	326	=
O	327	328	1
O	329	331	cm
O	331	332	,
O	333	335	by
O	336	347	speculation
O	348	352	that
O	353	362	tamoxifen
O	363	364	(
O	364	367	TAM
O	367	368	)
O	369	374	might
O	375	377	be
O	378	380	as
O	381	383	or
O	384	388	more
O	389	398	effective
O	399	403	than
O	404	413	radiation
O	414	421	therapy
O	422	423	(
O	423	426	XRT
O	426	427	)
O	428	430	in
O	431	439	reducing
O	440	443	the
O	444	448	rate
O	449	451	of
O	452	463	ipsilateral
O	464	470	breast
O	471	476	tumor
O	477	487	recurrence
O	488	489	(
O	489	493	IBTR
O	493	494	)
O	495	497	in
O	498	502	such
O	503	508	women
O	508	509	,
O	510	513	and
O	514	516	by
O	517	520	the
O	521	527	thesis
O	528	532	that
O	533	537	both
O	538	548	modalities
O	549	554	might
O	555	557	be
O	558	562	more
O	563	572	effective
O	573	577	than
O	578	584	either
O	585	590	alone
O	590	591	.

O	592	597	After
O	598	608	lumpectomy
O	608	609	,
B-total-participants	610	611	1
I-total-participants	611	612	,
I-total-participants	612	615	009
O	616	621	women
O	622	626	were
O	627	635	randomly
O	636	644	assigned
O	645	647	to
O	648	651	TAM
O	652	653	(
O	653	654	n
O	655	656	=
B-intervention-participants	657	660	336
O	660	661	)
O	661	662	,
B-control	663	666	XRT
I-control	667	670	and
I-control	671	678	placebo
O	679	680	(
O	680	681	n
O	682	683	=
B-control-participants	684	687	336
O	687	688	)
O	688	689	,
O	690	692	or
O	693	696	XRT
O	697	700	and
O	701	704	TAM
O	705	706	(
O	706	707	n
O	708	709	=
B-intervention-participants	710	713	337
O	713	714	)
O	714	715	.

B-outcome-Measure	716	721	Rates
I-outcome-Measure	722	724	of
I-outcome-Measure	725	729	IBTR
O	729	730	,
B-outcome-Measure	731	738	distant
I-outcome-Measure	739	749	recurrence
O	749	750	,
O	751	754	and
B-outcome-Measure	755	768	contralateral
I-outcome-Measure	769	775	breast
I-outcome-Measure	776	782	cancer
I-outcome-Measure	783	784	(
I-outcome-Measure	784	787	CBC
I-outcome-Measure	787	788	)
O	789	793	were
O	794	799	among
O	800	803	the
O	804	807	end
O	808	814	points
O	815	818	for
O	819	827	analysis
O	827	828	.

O	829	839	Cumulative
O	840	849	incidence
O	850	852	of
O	853	857	IBTR
O	858	861	and
O	862	864	of
O	865	868	CBC
O	869	872	was
O	873	881	computed
O	882	892	accounting
O	893	896	for
O	897	906	competing
O	907	912	risks
O	912	913	.

O	914	921	Results
O	922	926	with
O	927	930	two
O	930	931	-
O	931	936	sided
O	937	938	P
O	939	945	values
O	946	948	of
O	948	949	.
O	949	951	05
O	952	954	or
O	955	959	less
O	960	964	were
O	965	978	statistically
O	979	990	significant
O	990	991	.

O	992	995	XRT
O	996	999	and
O	1000	1007	placebo
O	1008	1016	resulted
O	1017	1019	in
O	1020	1021	a
B-cv-bin-percent	1022	1024	49
I-cv-bin-percent	1024	1025	%
O	1026	1031	lower
B-outcome	1032	1038	hazard
I-outcome	1039	1043	rate
I-outcome	1044	1046	of
I-outcome	1047	1051	IBTR
O	1052	1056	than
O	1057	1060	did
O	1061	1064	TAM
O	1065	1070	alone
O	1070	1071	;
O	1072	1075	XRT
O	1076	1079	and
O	1080	1083	TAM
O	1084	1092	resulted
O	1093	1095	in
O	1096	1097	a
B-iv-bin-percent	1098	1100	63
I-iv-bin-percent	1100	1101	%
O	1102	1107	lower
O	1108	1112	rate
O	1113	1117	than
O	1118	1121	did
O	1122	1125	XRT
O	1126	1129	and
O	1130	1137	placebo
O	1137	1138	.

O	1139	1143	When
O	1144	1152	compared
O	1153	1157	with
O	1158	1161	TAM
O	1162	1167	alone
O	1167	1168	,
O	1169	1172	XRT
O	1173	1177	plus
O	1178	1181	TAM
O	1182	1190	resulted
O	1191	1193	in
O	1194	1196	an
B-iv-bin-percent	1197	1199	81
I-iv-bin-percent	1199	1200	%
B-outcome	1201	1210	reduction
I-outcome	1211	1213	in
I-outcome	1214	1220	hazard
I-outcome	1221	1225	rate
I-outcome	1226	1228	of
I-outcome	1229	1233	IBTR
O	1233	1234	.

B-outcome	1235	1245	Cumulative
I-outcome	1246	1255	incidence
I-outcome	1256	1258	of
I-outcome	1259	1263	IBTR
O	1264	1271	through
O	1272	1273	8
O	1274	1279	years
O	1280	1283	was
B-iv-bin-percent	1284	1286	16
I-iv-bin-percent	1286	1287	.
I-iv-bin-percent	1287	1288	5
I-iv-bin-percent	1288	1289	%
O	1290	1294	with
O	1295	1298	TAM
O	1298	1299	,
B-cv-bin-percent	1300	1301	9
I-cv-bin-percent	1301	1302	.
I-cv-bin-percent	1302	1303	3
I-cv-bin-percent	1303	1304	%
O	1305	1309	with
O	1310	1313	XRT
O	1314	1317	and
O	1318	1325	placebo
O	1325	1326	,
O	1327	1330	and
B-iv-bin-percent	1331	1332	2
I-iv-bin-percent	1332	1333	.
I-iv-bin-percent	1333	1334	8
I-iv-bin-percent	1334	1335	%
O	1336	1340	with
O	1341	1344	XRT
O	1345	1348	and
O	1349	1352	TAM
O	1352	1353	.

O	1354	1357	XRT
O	1358	1365	reduced
O	1366	1370	IBTR
O	1371	1376	below
O	1377	1380	the
O	1381	1386	level
O	1387	1395	achieved
O	1396	1400	with
O	1401	1404	TAM
O	1405	1410	alone
O	1410	1411	,
O	1412	1422	regardless
O	1423	1425	of
O	1426	1434	estrogen
O	1435	1443	receptor
O	1444	1445	(
O	1445	1447	ER
O	1447	1448	)
O	1449	1455	status
O	1455	1456	.

B-outcome	1457	1464	Distant
I-outcome	1465	1474	treatment
I-outcome	1475	1483	failures
O	1484	1488	were
O	1489	1499	infrequent
O	1500	1503	and
O	1504	1507	not
O	1508	1521	significantly
O	1522	1531	different
O	1532	1537	among
O	1538	1541	the
O	1542	1548	groups
O	1549	1550	(
O	1550	1551	P
O	1552	1553	=
O	1553	1554	.
O	1554	1556	28
O	1556	1557	)
O	1557	1558	.

O	1559	1563	When
O	1564	1567	TAM
O	1567	1568	-
O	1568	1575	treated
O	1576	1581	women
O	1582	1586	were
O	1587	1595	compared
O	1596	1600	with
O	1601	1606	those
O	1607	1610	who
O	1611	1619	received
O	1620	1623	XRT
O	1624	1627	and
O	1628	1635	placebo
O	1635	1636	,
O	1637	1642	there
O	1643	1646	was
O	1647	1648	a
O	1649	1660	significant
B-outcome	1661	1670	reduction
I-outcome	1671	1673	in
I-outcome	1674	1677	CBC
O	1678	1679	(
O	1679	1685	hazard
O	1686	1691	ratio
O	1691	1692	,
O	1693	1694	0
O	1694	1695	.
O	1695	1697	45
O	1697	1698	;
O	1699	1701	95
O	1701	1702	%
O	1703	1713	confidence
O	1714	1722	interval
O	1722	1723	,
O	1724	1725	0
O	1725	1726	.
O	1726	1728	21
O	1729	1731	to
O	1732	1733	0
O	1733	1734	.
O	1734	1736	95
O	1736	1737	;
O	1738	1739	P
O	1740	1741	=
O	1741	1742	.
O	1742	1745	039
O	1745	1746	)
O	1746	1747	.

B-outcome	1748	1756	Survival
O	1757	1759	in
O	1760	1763	the
O	1764	1769	three
O	1770	1776	groups
O	1777	1780	was
B-iv-bin-percent	1781	1783	93
I-iv-bin-percent	1783	1784	%
O	1784	1785	,
B-cv-bin-percent	1786	1788	94
I-cv-bin-percent	1788	1789	%
O	1789	1790	,
O	1791	1794	and
B-iv-bin-percent	1795	1797	93
I-iv-bin-percent	1797	1798	%
O	1798	1799	,
O	1800	1812	respectively
O	1813	1814	(
O	1814	1815	P
O	1816	1817	=
O	1817	1818	.
O	1818	1820	93
O	1820	1821	)
O	1821	1822	.

O	1823	1825	In
O	1826	1831	women
O	1832	1836	with
O	1837	1843	tumors
O	1844	1845	<
O	1845	1846	/
O	1846	1847	=
O	1848	1849	1
O	1850	1852	cm
O	1852	1853	,
O	1854	1858	IBTR
O	1859	1865	occurs
O	1866	1870	with
O	1871	1877	enough
O	1878	1887	frequency
O	1888	1893	after
O	1894	1904	lumpectomy
O	1905	1907	to
O	1908	1915	justify
O	1916	1927	considering
O	1928	1931	XRT
O	1931	1932	,
O	1933	1943	regardless
O	1944	1946	of
O	1947	1952	tumor
O	1953	1955	ER
O	1956	1962	status
O	1962	1963	,
O	1964	1967	and
O	1968	1971	TAM
O	1972	1976	plus
O	1977	1980	XRT
O	1981	1985	when
O	1986	1992	tumors
O	1993	1996	are
O	1997	1999	ER
O	2000	2008	positive
O	2008	2009	.
